✦ LIBER ✦

PUK12 ECONOMIC EVALUATION ON THE USE OF OXYBUTYNIN, TOLTERODINE, AND SOLIFENACIN IN PATIENTS WITH HYPERACTIVE BLADDER

✍ Scribed by A De Lago Acosta; G Salinas; J Idrovo; L Zapata; A Alanis; I Rico

Book ID: 118610052
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 77 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)72367-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PUK11 A COST-UTILITY ANALYSIS OF SOLIFEN

PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)

✍ L Cardozo; A Thorpe; M Grishchenko; MK Sidhu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

The cost-effectiveness of solifenacin vs

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service

✍ Linda Cardozo; Andrew Thorpe; Juliet Warner; Manpreet Sidhu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB

THE COST-EFFECTIVENESS OF SOLIFENACIN VS

THE COST-EFFECTIVENESS OF SOLIFENACIN VS FESOTERODINE, OXYBUTYNIN IMMEDIATE-RELEASE, PROPIVERINE, TOLTERODINE EXTENDED-RELEASE AND TOLTERODINE IMMEDIATE-RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UK NATIONAL HEALTH SERVICE

✍ Juliet L. Warner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

TOLERABILITY OF SOLIFENACIN IN COMPARISO

TOLERABILITY OF SOLIFENACIN IN COMPARISON WITH OXYBUTYNIN IMMEDIATE RELEASE IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS OF THE VECTOR STUDY

✍ Herschorn, Sender; Pommerville, Peter; Stothers, Lynn; Egerdie, Blair; Gajewski, 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 50 KB

PUK10 Cost-Effectiveness Analysis of Sol

PUK10 Cost-Effectiveness Analysis of Solifenacin Versus Oxybutynin Immediate-Release in the Treatment of Patients with Overactive Bladder in the United Kingdom

✍ W.M. Hart; V. Munro; P. Retsa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Randomized, double-blind placebo- and to

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

✍ C.R. Chapple; T. Rechberger; S. Al-Shukri; P. Meffan; K. Everaert; M. Huang; A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB